{"id":69091,"date":"2026-06-30T12:05:07","date_gmt":"2026-06-30T04:05:07","guid":{"rendered":"https:\/\/flcube.com\/?p=69091"},"modified":"2026-06-30T12:05:08","modified_gmt":"2026-06-30T04:05:08","slug":"anhui-wanbang-pharmaceutical-to-acquire-75-52-stake-in-cro-ctsmed-for-rmb-302m-expands-clinical-research-capabilities-through-strategic-vertical-integration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69091","title":{"rendered":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Anhui Wanbang Pharmaceutical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/301520:SHE\">SHE: 301520<\/a>) announced it will acquire a <strong>75.52% equity stake<\/strong> in <strong>Anhui CTSMED Pharmaceutical Technology Co., Ltd.<\/strong> for <strong>RMB 302.0776 million<\/strong> ($41.8 million) in an all-cash transaction, establishing CTSMED as a <strong>controlling subsidiary<\/strong> and significantly expanding Wanbang&#8217;s clinical research service capabilities.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Anhui CTSMED Pharmaceutical Technology Co., Ltd.<\/td><\/tr><tr><td><strong>Stake Acquired<\/strong><\/td><td>75.52% equity interest<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>RMB 302.0776 million (approximately $41.8 million)<\/td><\/tr><tr><td><strong>Payment Method<\/strong><\/td><td>All-cash consideration<\/td><\/tr><tr><td><strong>Post-Transaction Status<\/strong><\/td><td>CTSMED becomes controlling subsidiary of Wanbang<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>June 26, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-target-company-profile-ctsmed\" class=\"wp-block-heading\">Target Company Profile: CTSMED<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded<\/strong>: 2010<\/li>\n\n\n\n<li><strong>Business Model<\/strong>: Professional contract research organization (CRO) specializing in innovative drug clinical trials<\/li>\n\n\n\n<li><strong>Service Scope<\/strong>: Integrated, full-process clinical drug research services for global pharmaceutical enterprises and scientific research institutions<\/li>\n\n\n\n<li><strong>Core Capabilities<\/strong>: End-to-end clinical trial chain coverage from strategic planning through post-marketing studies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">CTSMED&#8217;s comprehensive service portfolio includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Medical Strategic Planning<\/strong>: Protocol design and development strategy<\/li>\n\n\n\n<li><strong>Phase I-III Clinical Operations<\/strong>: Full execution of clinical trial phases<\/li>\n\n\n\n<li><strong>Regulatory Dossier Writing<\/strong>: Marketing authorization application preparation<\/li>\n\n\n\n<li><strong>Post-Marketing Clinical Studies<\/strong>: Phase IV and real-world evidence generation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-context\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Driver<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Vertical Integration<\/strong><\/td><td>Enhances Wanbang&#8217;s drug development ecosystem with in-house clinical research capabilities<\/td><\/tr><tr><td><strong>China CRO Market Growth<\/strong><\/td><td>Domestic CRO market projected to reach RMB 200 billion ($27.7 billion) by 2028, growing at 18% CAGR<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Positions Wanbang as integrated pharma-CRO player competing with larger domestic and international CROs<\/td><\/tr><tr><td><strong>Revenue Diversification<\/strong><\/td><td>Adds recurring service revenue stream to complement pharmaceutical product sales<\/td><\/tr><tr><td><strong>Global Ambitions<\/strong><\/td><td>Leverages CTSMED&#8217;s international client base to expand Wanbang&#8217;s global footprint<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">China&#8217;s pharmaceutical industry continues its rapid evolution toward innovation-driven development, with the National Medical Products Administration (NMPA) implementing reforms that accelerate drug approval timelines and encourage domestic innovation. This regulatory environment has created substantial demand for high-quality CRO services capable of supporting both domestic and international clinical development programs.<\/p>\n\n\n\n<h2 id=\"h-financial-impact-amp-integration-strategy\" class=\"wp-block-heading\">Financial Impact &amp; Integration Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The RMB 302 million acquisition represents a strategic investment that provides Wanbang with immediate access to established clinical research infrastructure, experienced personnel, and a diversified client portfolio. CTSMED&#8217;s end-to-end capabilities eliminate the need for Wanbang to develop clinical research competencies organically, accelerating time-to-market for the company&#8217;s internal pipeline while generating external revenue from third-party clients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction is expected to be accretive to Wanbang&#8217;s earnings within the first year post-closing, with synergies realized through shared infrastructure, cross-selling opportunities, and operational efficiencies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, integration, and financial impact. Actual results may differ due to risks including regulatory approvals, integration challenges, and competitive dynamics in the CRO market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e07\u90a6\u533b\u836f\uff1a\u5173\u4e8e\u6536\u8d2d\u5b89\u5fbd\u8d5b\u5fb7\u76db\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f875.52\u80a1\u6743\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e07\u90a6\u533b\u836f\uff1a\u5173\u4e8e\u6536\u8d2d\u5b89\u5fbd\u8d5b\u5fb7\u76db\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f875.52%\u80a1\u6743\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-b7edb4df-5f2a-4dc0-a766-8c20f75daefd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e07\u90a6\u533b\u836f\uff1a\u5173\u4e8e\u6536\u8d2d\u5b89\u5fbd\u8d5b\u5fb7\u76db\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f875.52\u80a1\u6743\u7684\u516c\u544a.pdf\">\u4e07\u90a6\u533b\u836f\uff1a\u5173\u4e8e\u6536\u8d2d\u5b89\u5fbd\u8d5b\u5fb7\u76db\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f875.52%\u80a1\u6743\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e07\u90a6\u533b\u836f\uff1a\u5173\u4e8e\u6536\u8d2d\u5b89\u5fbd\u8d5b\u5fb7\u76db\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f875.52\u80a1\u6743\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b7edb4df-5f2a-4dc0-a766-8c20f75daefd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[19,4825,3834,4826],"class_list":["post-69091","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-ctsmed-pharmaceutical-technology","tag-fosun-wanbang-pharmaceutical","tag-she-301520"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang&#039;s clinical research service capabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69091\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration\" \/>\n<meta property=\"og:description\" content=\"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang&#039;s clinical research service capabilities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69091\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T04:05:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-30T04:05:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration\",\"datePublished\":\"2026-06-30T04:05:07+00:00\",\"dateModified\":\"2026-06-30T04:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"CTSMED Pharmaceutical Technology\",\"Fosun Wanbang Pharmaceutical\",\"SHE: 301520\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69091#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69091\",\"name\":\"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-30T04:05:07+00:00\",\"dateModified\":\"2026-06-30T04:05:08+00:00\",\"description\":\"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang's clinical research service capabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69091\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69091#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration - Insight, China&#039;s Pharmaceutical Industry","description":"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang's clinical research service capabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69091","og_locale":"en_US","og_type":"article","og_title":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration","og_description":"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang's clinical research service capabilities.","og_url":"https:\/\/flcube.com\/?p=69091","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T04:05:07+00:00","article_modified_time":"2026-06-30T04:05:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69091#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69091"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration","datePublished":"2026-06-30T04:05:07+00:00","dateModified":"2026-06-30T04:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69091"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","CTSMED Pharmaceutical Technology","Fosun Wanbang Pharmaceutical","SHE: 301520"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69091#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69091","url":"https:\/\/flcube.com\/?p=69091","name":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-30T04:05:07+00:00","dateModified":"2026-06-30T04:05:08+00:00","description":"Anhui Wanbang Pharmaceutical Technology Co., Ltd. (SHE: 301520) announced it will acquire a 75.52% equity stake in Anhui CTSMED Pharmaceutical Technology Co., Ltd. for RMB 302.0776 million ($41.8 million) in an all-cash transaction, establishing CTSMED as a controlling subsidiary and significantly expanding Wanbang's clinical research service capabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69091#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69091"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69091#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M \u2013 Expands Clinical Research Capabilities Through Strategic Vertical Integration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69091"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69091\/revisions"}],"predecessor-version":[{"id":69094,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69091\/revisions\/69094"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}